Renal problems after bone marrow transplantation

被引：0
作者：
Kemmner S. [1 ]
Heemann U. [1 ]
机构：
[1] Abteilung für Nephrologie, Klinikum rechts der Isar, Ismaningerstr. 22, München
来源：
Der Nephrologe | 2016年 / 11卷 / 3期
关键词：
Acute kidney failure; Bone marrow transplantation; Graft versus host disease; Renal dysfunction; Thrombotic microangiopathy;
D O I：
10.1007/s11560-016-0057-2
中图分类号：
学科分类号：
摘要：
Acute renal failure (ARF) is one of the most frequent complications following bone marrow transplantation and is a major risk factor for survival as well as for the development of chronic renal insufficiency. Apart from the underlying disease, the choice of chemotherapeutic drugs, the degree of histocompatibility as well as the array and intensity of radiation therapy are responsible for the occurrence of ARF. The main cause of ARF is the occurrence of thrombotic microangiopathy mostly resulting from graft versus host disease. This complication is associated with a very high mortality and must be treated as quickly as possible. Possible therapeutic interventional strategies apart from plasma exchange are the administration of rituximab and eculizumab. © 2016, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码：205 / 210
页数：5
相关论文
共 22 条
[1]  
Au W.Y., Ma E.S., Lee T.L., Et al., Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab, Br J Haemato, 137, pp. 475-478, (2007)
[2]  
Brukamp K., Doyle A.M., Bloom R.D., Et al., Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease?, Clin J Am Soc Nephro, 1, pp. 685-694, (2006)
[3]  
Changsirikulchai S., Myerson D., Guthrie K.A., Et al., Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis, Clin J Am Soc Nephro, 4, pp. 345-353, (2009)
[4]  
Cheng J.C., Schultheiss T.E., Wong J.Y., Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation, Int J Radiat Oncol Biol Phy, 71, pp. 1436-1443, (2008)
[5]  
De Fontbrune F.S., Galambrun C., Sirvent A., Et al., Use of Eculizumab in patients with Allogeneic stem cell transplant-associated thrombotic Microangiopathy: a study from the SFGM-TC, Transplantatio, 99, pp. 1953-1959, (2015)
[6]  
El-Seisi S., Gupta R., Clase C.M., Et al., Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation, Biol Blood Marrow Transplan, 9, pp. 683-688, (2003)
[7]  
Fernandez C., Lario A., Fores R., Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease, Hematology report, 7, (2015)
[8]  
George J.N., Li X., Mcminn J.R., Et al., Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma, Transfusio, 44, pp. 294-304, (2004)
[9]  
Gooley T.A., Chien J.W., Pergam S.A., Et al., Reduced mortality after allogeneic hematopoietic-cell transplantation, N Engl J Me, 363, pp. 2091-2101, (2010)
[10]  
Hingorani S.R., Seidel K., Lindner A., Et al., Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival, Biol Blood Marrow Transplan, 14, pp. 1365-1372, (2008)
123